FDA new drug approvals in Q3 2026
vol.25 iss.11 (2026) pp.2 Filling the massive AI drug discovery data gap.
vol.25 iss.11 (2026) Novel drug treatments for schizophrenia.
(2026) Prime editing to suppress nonsense mutations.
(2026) Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) 2025 FDA approvals.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Kinase inhibitors trigger target degradation.
(2026) Boosting CAR T cell efficacy.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.
(2026) TIGIT's immuno-oncology teachings.
(2026) Approvals by the China NMPA in 2025.
(2026) PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.
(2026) GSK pays US$2 billion for prophylactic food allergen antibody.
(2026) 2025's FDA approvals by regulatory designations.
(2026) Unlocking the potential of disease prevention through regulatory science.
(2026) Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.
(2026) Two-step screen for CARD9 inhibitors.
(2026) Predicting small-molecule-RNA interactions.
(2026) Lipid flippase inhibitor tackles drug-resistant fungi.
(2026) Spatiotemporal in vivo protein degradation.
(2026) Mapping covalent drug targets.
(2026) Accelerating the drug regulatory process through a federated cloud ecosystem.
(2026) Dose-finding and optimization in drug development for rare diseases.
(2026) The therapeutic potential of orphan adhesion G-protein-coupled receptors.
(2026) Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate.
(2026) Clearing cholesterol combats secondary lymphoedema.
(2026) The pancreatic cancer drug market.
(2026) PIP4K2C: an emerging fulcrum for multiple diseases.
(2026) FDA approves dwarfism drug.
(2026) Top companies and drugs by sales in 2025.
(2026) Digital endpoints in clinical trials: building the business case for systematic adoption.
(2026) Author Correction: Novel drug treatments for schizophrenia.
(2026) An allosteric site on cereblon.
(2026) Promoting remyelination.
(2026) Inhibiting advillin in glioblastoma.
(2026) Targeting vascular smooth muscle cells.
(2026)
vol.25 iss.11 (2026) pp.2 Filling the massive AI drug discovery data gap.
vol.25 iss.11 (2026) Novel drug treatments for schizophrenia.
(2026) Prime editing to suppress nonsense mutations.
(2026) Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) 2025 FDA approvals.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Kinase inhibitors trigger target degradation.
(2026) Boosting CAR T cell efficacy.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.
(2026) TIGIT's immuno-oncology teachings.
(2026) Approvals by the China NMPA in 2025.
(2026) PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.
(2026) GSK pays US$2 billion for prophylactic food allergen antibody.
(2026) 2025's FDA approvals by regulatory designations.
(2026) Unlocking the potential of disease prevention through regulatory science.
(2026) Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.
(2026) Two-step screen for CARD9 inhibitors.
(2026) Predicting small-molecule-RNA interactions.
(2026) Lipid flippase inhibitor tackles drug-resistant fungi.
(2026) Spatiotemporal in vivo protein degradation.
(2026) Mapping covalent drug targets.
(2026) Accelerating the drug regulatory process through a federated cloud ecosystem.
(2026) Dose-finding and optimization in drug development for rare diseases.
(2026) The therapeutic potential of orphan adhesion G-protein-coupled receptors.
(2026) Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate.
(2026) Clearing cholesterol combats secondary lymphoedema.
(2026) The pancreatic cancer drug market.
(2026) PIP4K2C: an emerging fulcrum for multiple diseases.
(2026) FDA approves dwarfism drug.
(2026) Top companies and drugs by sales in 2025.
(2026) Digital endpoints in clinical trials: building the business case for systematic adoption.
(2026) Author Correction: Novel drug treatments for schizophrenia.
(2026) An allosteric site on cereblon.
(2026) Promoting remyelination.
(2026) Inhibiting advillin in glioblastoma.
(2026) Targeting vascular smooth muscle cells.
(2026)